Back
Corporate News
Lupin launches Sugammadex Injection in the U.S. after FDA approval
31-Jul-2026, 12:31
Lupin Limited announced the launch of Sugammadex Injection, 200 mg/2 mL and 500 mg/5 mL single-dose vial in the United States following approval from the United States Food and Drug Administration, with the product being bioequivalent to Bridion® Injection of Merck, Sharp & Dohme LLC.
Lupin Limited announced the launch of Sugammadex Injection, 200 mg/2 mL and 500 mg/5 mL single-dose vial in the United States following approval from the United States Food and Drug Administration, with the product being bioequivalent to Bridion® Injection of Merck, Sharp & Dohme LLC.